Lercanidipine Hydrochloride Teva Uk

Lercanidipine, the active ingredient in Lercanidipine Hydrochloride Teva Uk, is a calcium channel blocker presented as a tablet for oral use. It lowers elevated blood pressure in adults with hypertension. GNH USA supplies Lercanidipine Hydrochloride Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class and is used to manage high blood pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to control essential hypertension. Cardiovascular risk reduction: contributes to lower risk of stroke and heart attack by maintaining target blood pressure levels.

Lercanidipine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or feet. - Dizziness or light‑headedness, especially after the first dose. - Palpitations: awareness of heartbeats. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or hives. - Angioedema: swelling of the face, lips, tongue, or throat. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with lercanidipine, certain precautions should be observed.

Monitor blood pressure: ensure adequate control and avoid excessive lowering. Assess hepatic function: use caution in patients with liver impairment. Avoid abrupt discontinuation: tapering may be needed to prevent rebound hypertension. Review concomitant cardiovascular drugs: consider additive effects with other antihypertensives. Educate patients on orthostatic changes: advise rising slowly from sitting or lying positions. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine may interact with several other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Other calcium‑channel blockers (e.g., amlodipine): additive vasodilatory effect can cause severe hypotension. - Grapefruit juice: inhibits metabolism and raises drug concentration.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers (e.g., metoprolol): combined use can enhance blood‑pressure lowering. - Diuretics (e.g., thiazides): may increase risk of electrolyte imbalance and hypotension. - ACE inhibitors or ARBs: monitor for excessive blood‑pressure reduction. - NSAIDs: may blunt antihypertensive response.